|
US4450150A
(en)
|
1973-05-17 |
1984-05-22 |
Arthur D. Little, Inc. |
Biodegradable, implantable drug delivery depots, and method for preparing and using the same
|
|
US4275152A
(en)
|
1977-02-03 |
1981-06-23 |
Eastman Kodak Company |
Hydrolysis of protein-bound cholesterol esters
|
|
PT83613B
(en)
|
1985-10-28 |
1988-11-21 |
Lilly Co Eli |
Process for the selective chemical removal of a protein amino-terminal residue
|
|
WO1987005330A1
(fr)
|
1986-03-07 |
1987-09-11 |
Michel Louis Eugene Bergh |
Procede pour ameliorer la stabilite des glycoproteines
|
|
IN165717B
(fr)
|
1986-08-07 |
1989-12-23 |
Battelle Memorial Institute |
|
|
NZ232562A
(en)
|
1989-02-17 |
1992-10-28 |
Coselco Mimotopes Pty Ltd |
Immobilised peptide - solid support comprising a cleavable ester link between the peptide carboxy terminus and the solid support
|
|
DE69129226T2
(de)
|
1990-01-24 |
1998-07-30 |
Douglas I. Woodside Calif. Buckley |
Glp-1-analoga verwendbar in der diabetesbehandlung
|
|
CA2024855C
(fr)
|
1990-09-07 |
1997-12-09 |
Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee |
Procede et intermediaires pour la production du glucagon
|
|
JPH04145099A
(ja)
|
1990-10-05 |
1992-05-19 |
Sanwa Kagaku Kenkyusho Co Ltd |
Ｇｉｐ様活性を有するポリペプチド誘導体及びその用途
|
|
US5510459A
(en)
|
1991-01-17 |
1996-04-23 |
Zymogenetics, Inc. |
Glucagon antagonists
|
|
JP3266311B2
(ja)
|
1991-05-02 |
2002-03-18 |
生化学工業株式会社 |
新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
|
|
US5359030A
(en)
|
1993-05-10 |
1994-10-25 |
Protein Delivery, Inc. |
Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
|
|
US5480867A
(en)
|
1993-12-29 |
1996-01-02 |
The Rockefeller University |
Glucagon analogs with serine replacements
|
|
US5512549A
(en)
|
1994-10-18 |
1996-04-30 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
|
|
US5869602A
(en)
|
1995-03-17 |
1999-02-09 |
Novo Nordisk A/S |
Peptide derivatives
|
|
DE19530865A1
(de)
|
1995-08-22 |
1997-02-27 |
Michael Dr Med Nauck |
Wirkstoff sowie Mittel zur parenteralen Ernährung
|
|
EP0879279A4
(fr)
|
1996-02-06 |
2000-07-12 |
Lilly Co Eli |
Therapie des diabetes
|
|
CA2257119A1
(fr)
|
1996-06-05 |
1997-12-11 |
Boehringer Mannheim Gmbh |
Analogues exendine, procedes permettant de les preparer et medicaments les contenant
|
|
WO1998011126A1
(fr)
|
1996-09-09 |
1998-03-19 |
Zealand Pharmaceuticals A/S |
Promedicaments peptidiques contenant une sequence de liaison alpha-hydroxyacide
|
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
|
WO1998024464A1
(fr)
|
1996-12-03 |
1998-06-11 |
Trustees Of Boston University |
Antagonistes specifiques du polypeptide glucodependant insulinotrope (gip)
|
|
EP1053752A1
(fr)
|
1998-02-10 |
2000-11-22 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Preparations a liberation controlee
|
|
JP4394279B2
(ja)
|
1998-03-09 |
2010-01-06 |
ジーランド ファーマ アクティーゼルスカブ |
酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
|
|
DE19828113A1
(de)
|
1998-06-24 |
2000-01-05 |
Probiodrug Ges Fuer Arzneim |
Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
|
|
US20030236190A1
(en)
|
1998-09-02 |
2003-12-25 |
Renuka Pillutla |
Isulin and IGF-1 receptor agonists and antagonists
|
|
AU6294899A
(en)
|
1998-10-07 |
2000-04-26 |
Medical College Of Georgia Research Institute, Inc. |
Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
|
|
GB2344287A
(en)
|
1998-12-03 |
2000-06-07 |
Ferring Bv |
Controlled release pharmaceutical formulation
|
|
JP2002534512A
(ja)
|
1999-01-15 |
2002-10-15 |
ノボ ノルディスク アクティーゼルスカブ |
非ペプチドｇｌｐ−１アゴニスト
|
|
GB0404124D0
(en)
|
2004-02-25 |
2004-03-31 |
Univ Ulster |
Antagonists of GIP
|
|
WO2000058360A2
(fr)
|
1999-03-29 |
2000-10-05 |
Uutech Limited |
Peptide
|
|
ATE252601T1
(de)
|
1999-05-17 |
2003-11-15 |
Conjuchem Inc |
Lang wirkende insulinotrope peptide
|
|
AU2001257278A1
(en)
|
2000-04-27 |
2001-11-07 |
Bionebraska, Inc. |
Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose
|
|
US6677136B2
(en)
|
2000-05-03 |
2004-01-13 |
Amgen Inc. |
Glucagon antagonists
|
|
EP1290019A2
(fr)
|
2000-06-14 |
2003-03-12 |
Cytovax Biotechnologies Inc. |
Utilisation d'un echafaudage structural a superhelice afin de generer des peptides specifiques de structure
|
|
KR100847615B1
(ko)
|
2000-06-16 |
2008-07-21 |
일라이 릴리 앤드 캄파니 |
글루카곤-유사 펩티드-1 유사체
|
|
JP2004509079A
(ja)
|
2000-08-02 |
2004-03-25 |
セラテクノロジーズ・インコーポレーテッド |
効力が増大した修飾生体ペプチド
|
|
US6262062B1
(en)
|
2000-08-15 |
2001-07-17 |
Cpd, Llc |
Method of treating the syndrome of coronary heart disease risk factors in humans
|
|
US6528520B2
(en)
|
2000-08-15 |
2003-03-04 |
Cpd, Llc |
Method of treating the syndrome of coronary heart disease risk factors in humans
|
|
US20020045572A1
(en)
|
2000-08-15 |
2002-04-18 |
Cpd, Llc |
Method of treating the syndrome of type 2 diabetes in humans
|
|
US6846831B2
(en)
|
2000-08-15 |
2005-01-25 |
Cpd, Llc |
Method of treating the syndrome of lipodystrophy
|
|
WO2002026265A2
(fr)
|
2000-09-29 |
2002-04-04 |
Schering Corporation |
Interleukine 10 pegylee
|
|
AU2002228608A1
(en)
|
2000-12-13 |
2002-06-24 |
Eli Lilly And Company |
Amidated glucagon-like peptide-1
|
|
DE60228972D1
(de)
|
2001-07-31 |
2008-10-30 |
Us Gov Health & Human Serv |
Glp 1 exendin 4 peptidanaloga und deren verwendungen
|
|
JP2005509409A
(ja)
|
2001-08-08 |
2005-04-14 |
ジェンザイム・コーポレーション |
糖尿病および他の血糖疾患の治療方法
|
|
US7238663B2
(en)
|
2001-08-28 |
2007-07-03 |
Eli Lilly And Company |
Pre-mixes of GLP-1 and basal insulin
|
|
GB0121709D0
(en)
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
|
AR036711A1
(es)
|
2001-10-05 |
2004-09-29 |
Bayer Corp |
Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
|
|
US7041646B2
(en)
|
2001-10-05 |
2006-05-09 |
Bayer Pharmaceuticals Corporation |
Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
|
|
CN1630709A
(zh)
|
2001-10-18 |
2005-06-22 |
百时美施贵宝公司 |
人胰高血糖素样多肽－1模拟物和它们在治疗糖尿病和相关状况中的应用
|
|
EP1448222A4
(fr)
|
2001-10-19 |
2006-05-17 |
Lilly Co Eli |
Melanges biphasiques de glp-1 et d'insuline
|
|
WO2003059378A2
(fr)
|
2001-12-29 |
2003-07-24 |
Novo Nordisk A/S |
Utilisation combinee d'un compose glp-1 et d'un autre medicament pour traiter la dyslipidemie
|
|
AR038102A1
(es)
|
2002-01-08 |
2004-12-29 |
Lilly Co Eli |
Analogos extendidos de peptido 1 de tipo glucagon
|
|
US20030232761A1
(en)
|
2002-03-28 |
2003-12-18 |
Hinke Simon A. |
Novel analogues of glucose-dependent insulinotropic polypeptide
|
|
AU2003239478A1
(en)
|
2002-06-04 |
2003-12-22 |
Eli Lilly And Company |
Modified glucagon-like peptide-1 analogs
|
|
AU2003237933A1
(en)
|
2002-06-11 |
2003-12-22 |
Cellartis Ab |
Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
|
|
EP1526864A4
(fr)
|
2002-06-15 |
2006-11-08 |
Enteromed Inc |
Prevention et traitement d'une steatose hepatique non alcoolique (nafld), par antagonisme du recepteur du polypeptide insulinotropique gluco-dependant (gip)
|
|
JP2006501820A
(ja)
|
2002-09-06 |
2006-01-19 |
バイエル・フアーマシユーチカルズ・コーポレーシヨン |
修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
|
|
US7917208B2
(en)
|
2002-10-04 |
2011-03-29 |
Microchips, Inc. |
Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
|
|
US7192922B2
(en)
|
2002-11-19 |
2007-03-20 |
Allegheny-Singer Research Institute |
Method of treating left ventricular dysfunction
|
|
WO2004063351A2
(fr)
|
2003-01-09 |
2004-07-29 |
Macrogenics, Inc. |
Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes
|
|
US20050059605A1
(en)
|
2003-01-31 |
2005-03-17 |
Krishna Peri |
Chemically modified metabolites of regulatory peptides and methods of producing and using same
|
|
WO2004078777A2
(fr)
|
2003-03-04 |
2004-09-16 |
Biorexis Pharmaceutical Corporation |
Proteines protegees contre la dipeptidylpeptidase
|
|
PL1605897T3
(pl)
|
2003-03-19 |
2012-12-31 |
Lilly Co Eli |
Związki będące połączeniem GLP-1 z poli(glikolem etylenowym)
|
|
AU2004228793B2
(en)
|
2003-04-08 |
2009-10-08 |
Yeda Research And Development Co. Ltd. |
Reversible pegylated drugs
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
AU2004240630B2
(en)
|
2003-05-15 |
2010-10-07 |
Trustees Of Tufts College |
Stable analogs of peptide and polypeptide therapeutics
|
|
WO2004105781A2
(fr)
|
2003-06-03 |
2004-12-09 |
Novo Nordisk A/S |
Compositions pharmaceutiques peptidiques stabilisees
|
|
WO2004105790A1
(fr)
|
2003-06-03 |
2004-12-09 |
Novo Nordisk A/S |
Compositions peptidiques pharmaceutiques stabilisees
|
|
CN101974090B
(zh)
|
2003-06-12 |
2015-06-17 |
伊莱利利公司 |
Glp-1类似物融合蛋白质
|
|
WO2004111078A2
(fr)
|
2003-06-18 |
2004-12-23 |
Theratechnologies Inc. |
Composes qui modulent la reponse du glucagon et utilisations associees
|
|
SI2932981T1
(sl)
|
2003-09-19 |
2021-11-30 |
Novo Nordisk A/S |
Albumin-vezavni derivati GLP-1
|
|
US7364875B2
(en)
|
2003-10-30 |
2008-04-29 |
Cresent Innovations, Inc. |
Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight
|
|
DE602004026113D1
(de)
|
2003-12-18 |
2010-04-29 |
Novo Nordisk As |
Glp-1-verbindungen
|
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
|
US20080318837A1
(en)
|
2003-12-26 |
2008-12-25 |
Nastech Pharmaceutical Company Inc. |
Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
|
|
US7442682B2
(en)
|
2004-10-19 |
2008-10-28 |
Nitto Denko Corporation |
Transepithelial delivery of peptides with incretin hormone activities
|
|
EA011653B1
(ru)
|
2005-02-11 |
2009-04-28 |
Амилин Фармасьютикалз, Инк. |
Аналоги и гибридные полипептиды gip с избираемыми свойствами
|
|
WO2007022123A2
(fr)
|
2005-08-11 |
2007-02-22 |
Amylin Pharmaceuticals, Inc. |
Polypeptides hybrides presentant des proprietes selectionnables
|
|
US20090062192A1
(en)
|
2005-03-18 |
2009-03-05 |
Novo Nordisk A/S |
Dimeric Peptide Agonists of the Glp-1 Receptor
|
|
WO2006121904A1
(fr)
|
2005-05-06 |
2006-11-16 |
Bayer Pharmaceuticals Corporation |
Agonistes du recepteur du polypeptide insulinotropique gluco-dependant (gip) et procedes pharmacologiques d'utilisation associes
|
|
PT1881850E
(pt)
|
2005-05-13 |
2010-11-26 |
Lilly Co Eli |
Compostos peguilados de glp-1
|
|
DK1891105T3
(da)
|
2005-06-13 |
2012-07-16 |
Imp Innovations Ltd |
Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd
|
|
EP1937716A2
(fr)
|
2005-09-08 |
2008-07-02 |
Uutech Limited |
Analogues de polypeptide inhibiteur gastrique comme traitement de la fonction reduite des cellules beta pancreatiques du fait du vieillissement
|
|
US20090170762A1
(en)
|
2005-09-08 |
2009-07-02 |
Uutech Limited |
Treatment of Diabetes Related Obesity
|
|
US7846445B2
(en)
|
2005-09-27 |
2010-12-07 |
Amunix Operating, Inc. |
Methods for production of unstructured recombinant polymers and uses thereof
|
|
CN101534846B
(zh)
|
2005-11-07 |
2014-11-05 |
印第安纳大学研究及科技有限公司 |
显示生理学溶解性和稳定性的胰高血糖素类似物
|
|
AU2007221366B2
(en)
|
2006-02-22 |
2012-08-23 |
Msd Italia S.R.L. |
Oxyntomodulin derivatives
|
|
ES2397659T3
(es)
|
2006-03-15 |
2013-03-08 |
Novo Nordisk A/S |
Mezclas de amilina e insulina
|
|
WO2007109354A2
(fr)
|
2006-03-21 |
2007-09-27 |
Amylin Pharmaceuticals, Inc. |
Conjugués inhibiteur de peptidase-peptide et procédés d'utilisation de ceux-ci
|
|
EP2574624A1
(fr)
|
2006-04-20 |
2013-04-03 |
Amgen Inc. |
Composés GLP-1
|
|
MX2008014418A
(es)
|
2006-05-15 |
2008-11-27 |
Wisconsin Alumni Res Found |
Administracion pulmonar de la 1 alfa, 25-dihidroxivitamina d3 y co-administracion de la homona paratiroidea o calcitonina.
|
|
FR2902092B1
(fr)
|
2006-06-07 |
2008-09-05 |
Sapelem Soc Par Actions Simpli |
Appareil de manutention de charge
|
|
WO2008022015A2
(fr)
|
2006-08-11 |
2008-02-21 |
Trustees Of Tufts College |
Analogues rétro-inverso de l'incrétine, et procédés pour leur utilisation
|
|
EP2057188B1
(fr)
|
2006-08-17 |
2013-07-31 |
Amylin Pharmaceuticals, LLC |
Analogue du gip et polypeptides hybrides possédant des propriétés sélectives
|
|
EP2057189B1
(fr)
|
2006-08-25 |
2013-03-06 |
Novo Nordisk A/S |
Composés d'exendine-4 acylée
|
|
EP2615108B1
(fr)
|
2006-09-08 |
2016-10-26 |
Ambrx, Inc. |
Polypeptide plasmatique humain modifié ou échafaudages fc et leur utilisations
|
|
US8617531B2
(en)
|
2006-12-14 |
2013-12-31 |
Bolder Biotechnology, Inc. |
Methods of making proteins and peptides containing a single free cysteine
|
|
ES2628063T3
(es)
|
2007-01-05 |
2017-08-01 |
Indiana University Research And Technology Corporation |
Análogos de glucagón que muestran una mayor solubilidad en tampones de pH fisiológicos
|
|
CA2677932A1
(fr)
*
|
2007-02-15 |
2008-08-21 |
Indiana University Research And Technology Corporation |
Co-agonistes des recepteurs du glucagon/glp-1
|
|
JP5302952B2
(ja)
|
2007-04-19 |
2013-10-02 |
ドン・ア・ファーム・カンパニー・リミテッド |
糖調節ペプチドの制御放出に適した生分解性マイクロスフェア組成物及びその製造方法
|
|
CN103298935A
(zh)
|
2007-08-15 |
2013-09-11 |
阿穆尼克斯公司 |
用于改善生物活性多肽性能的组合物和方法
|
|
EP2190872B1
(fr)
|
2007-09-05 |
2018-03-14 |
Novo Nordisk A/S |
Dérivés de glucagon-like peptide-1 et leur utilisation pharmaceutique
|
|
CN101842386A
(zh)
|
2007-09-05 |
2010-09-22 |
诺沃-诺迪斯克有限公司 |
截短的glp-1衍生物和它们的治疗用途
|
|
US20100256056A1
(en)
|
2007-09-07 |
2010-10-07 |
Zheng Xin Dong |
Analogues of exendin-4 and exendin-3
|
|
EP2036923A1
(fr)
|
2007-09-11 |
2009-03-18 |
Novo Nordisk A/S |
Dérivés d'amyline améliorés
|
|
WO2009034117A1
(fr)
|
2007-09-11 |
2009-03-19 |
Novo Nordisk A/S |
Mélange comprenant de l'amyline, qui est un peptide, et une insuline retard
|
|
EP2036539A1
(fr)
|
2007-09-11 |
2009-03-18 |
Novo Nordisk A/S |
Formulations stables d'amyline et ses analogues
|
|
US8980830B2
(en)
|
2007-10-30 |
2015-03-17 |
Indiana University Research And Technology Corporation |
Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
|
|
WO2009058662A2
(fr)
|
2007-10-30 |
2009-05-07 |
Indiana University Research And Technology Corporation |
Antagonistes du glucagon
|
|
CA2713348C
(fr)
*
|
2008-01-30 |
2018-10-09 |
Indiana University Research And Technology Corporation |
Promedicaments peptidiques a base d'esters
|
|
BRPI0906643A2
(pt)
|
2008-02-01 |
2019-09-10 |
Ascendis Pharma As |
profármaco compreendendo um conjugado fármaco-ligante
|
|
US8450270B2
(en)
|
2008-06-17 |
2013-05-28 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
|
|
MX2010013454A
(es)
*
|
2008-06-17 |
2011-01-21 |
Tion Indiana University Res And Technology Corpora |
Co-agonistas de receptor de glucagon/glp-1.
|
|
HUE028072T2
(en)
|
2008-06-17 |
2016-11-28 |
Univ Indiana Res & Tech Corp |
GIP-based agonists for the treatment of metabolic disease and obesity
|
|
RU2578591C2
(ru)
|
2008-12-19 |
2016-03-27 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Лекарственные средства, связанные с дипептидами
|
|
KR20110110174A
(ko)
|
2008-12-19 |
2011-10-06 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
아미드 기반 글루카곤 슈퍼패밀리 펩티드 프로드럭
|
|
WO2010096052A1
(fr)
|
2009-02-19 |
2010-08-26 |
Merck Sharp & Dohme Corp. |
Analogues d'oxyntomoduline
|
|
IN2012DN00377A
(fr)
*
|
2009-06-16 |
2015-08-21 |
Univ Indiana Res & Tech Corp |
|
|
WO2011075393A2
(fr)
|
2009-12-18 |
2011-06-23 |
Indiana University Research And Technology Corporation |
Co-agonistes du récepteur du glucagon/glp-i
|
|
JO2976B1
(en)
|
2009-12-22 |
2016-03-15 |
ايلي ليلي اند كومباني |
Axentomodulin polypeptide
|
|
AR079344A1
(es)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
|
|
JP2013518115A
(ja)
|
2010-01-27 |
2013-05-20 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション |
代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物
|
|
AR080592A1
(es)
|
2010-03-26 |
2012-04-18 |
Lilly Co Eli |
Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
|
|
ES2661228T3
(es)
|
2010-05-13 |
2018-03-28 |
Indiana University Research And Technology Corporation |
Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
|
|
JP6050746B2
(ja)
|
2010-05-13 |
2016-12-21 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
|
|
KR20130102470A
(ko)
|
2010-06-24 |
2013-09-17 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그
|
|
WO2011163473A1
(fr)
|
2010-06-25 |
2011-12-29 |
Indiana University Research And Technology Corporation |
Analogues du glucagon présentant une solubilité et une stabilité améliorées dans des tampons à ph physiologique
|
|
KR20130132931A
(ko)
*
|
2010-12-22 |
2013-12-05 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
Gip 수용체 활성을 나타내는 글루카곤 유사체들
|